The oxytetracycline suppresses stemness [Fig. 3C] through inducing of CD133 degradation [Figs 3B, 4D] and thereby it facilitates anticancer therapeutic efficacy in HCC in vivo [Fig. 5]. This evidence concerns the gene PROM1 and hepatocellular carcinoma.